Akero Therapeutics, Inc.
AKRO
$54.63
-$0.06-0.11%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -12.19% | -25.93% | -32.58% | -26.89% | -83.33% |
| Total Depreciation and Amortization | -- | -- | -- | 650.00% | -80.00% |
| Total Amortization of Deferred Charges | 9.15% | 18.47% | 58.93% | 45.00% | 41.38% |
| Total Other Non-Cash Items | 104.90% | 21.54% | 29.37% | 64.77% | 54.88% |
| Change in Net Operating Assets | 442.79% | 327.77% | -127.58% | -135.36% | 85.81% |
| Cash from Operations | 4.62% | 16.03% | -92.56% | -37.97% | -41.64% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -22.29% | 131.13% | -933.52% | 19.44% | 158.13% |
| Cash from Investing | -22.29% | 131.00% | -933.52% | 19.44% | 158.13% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 7.67% | 949.85% | 10.89% | 14,162.66% | 288.46% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | 100.00% | -110.22% | 6.45% | -- |
| Cash from Financing | -1,209.46% | 2,388.67% | 7.79% | 15,037.65% | 280.52% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -877.88% | 111.01% | -139.60% | 168.40% | 103.27% |